Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Schmittel
A
A
Jahnke
K
K
Thiel
E
E
Keilholz
U
U
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000930:Antidiarrheals / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003967:Diarrhea / Q000139:chemically induced* / Q000517:prevention & control*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008139:Loperamide / Q000627:therapeutic use; D009355:Neomycin / Q000494:pharmacology* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000930:Antidiarrheals; D000972:Antineoplastic Agents, Phytogenic; D008139:Loperamide; D000077146:Irinotecan; D009355:Neomycin; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin